Status:
COMPLETED
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Primary Objective: To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo. Secondary Objective: To assess the response of subjects receiv...
Eligibility Criteria
Inclusion
- Outpatients
- Sexually active women participating in the study must use a medically acceptable form of contraception
- Subjects must have a primary diagnosis of major depressive disorder of 4 on Clinical Global Impressions-Severity scale (CGI-S)
Exclusion
- Treatment with DVS-233 SR at any time in the past
- Treatment with venlafaxine (immediate release \[IR\] or extended release \[ER\]) within 90 days of study day 1
- Known hypersensitivity to venlafaxine (IR or ER)
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2004
Estimated Enrollment :
375 Patients enrolled
Trial Details
Trial ID
NCT00073762
End Date
September 1 2004
Last Update
August 19 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.